MA47215A - Procédés prédictifs et diagnostiques pour le cancer de la prostate - Google Patents
Procédés prédictifs et diagnostiques pour le cancer de la prostateInfo
- Publication number
- MA47215A MA47215A MA047215A MA47215A MA47215A MA 47215 A MA47215 A MA 47215A MA 047215 A MA047215 A MA 047215A MA 47215 A MA47215 A MA 47215A MA 47215 A MA47215 A MA 47215A
- Authority
- MA
- Morocco
- Prior art keywords
- predictive
- prostate cancer
- diagnostic procedures
- diagnostic
- procedures
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443831P | 2017-01-09 | 2017-01-09 | |
| US201762473507P | 2017-03-20 | 2017-03-20 | |
| US201762561218P | 2017-09-21 | 2017-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47215A true MA47215A (fr) | 2019-11-13 |
Family
ID=62791142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047215A MA47215A (fr) | 2017-01-09 | 2018-01-09 | Procédés prédictifs et diagnostiques pour le cancer de la prostate |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11613785B2 (fr) |
| EP (1) | EP3565560B1 (fr) |
| ES (1) | ES2988845T3 (fr) |
| MA (1) | MA47215A (fr) |
| WO (1) | WO2018129497A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116059219A (zh) | 2015-07-16 | 2023-05-05 | 比奥克斯塞尔医疗股份有限公司 | 一种使用免疫调节治疗癌症的新颖方法 |
| US11613785B2 (en) | 2017-01-09 | 2023-03-28 | Onkosxcel Therapeutics, Llc | Predictive and diagnostic methods for prostate cancer |
| US20220089733A1 (en) * | 2018-12-10 | 2022-03-24 | Bioxcel Therapeutics, Inc. | Novel approach for treatment of cancer using immunomodulation |
| EP3893888A4 (fr) * | 2018-12-10 | 2022-08-31 | Bioxcel Therapeutics, Inc. | Traitements combinés pour traiter des maladies à l'aide d'un agent modifiant l'immunité innée et d'un agoniste de l'ox40 |
| KR20230125672A (ko) * | 2022-02-21 | 2023-08-29 | 사회복지법인 삼성생명공익재단 | 암 환자에 대한 면역관문억제제의 반응성 예측용 조성물 |
| WO2024097856A1 (fr) * | 2022-11-03 | 2024-05-10 | Onkosxcel Therapeutics, Llc | Biomarqueurs prédictifs pour la réactivité à des inhibiteurs de dpp dans des cancers |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| EP1498427B1 (fr) | 1992-08-21 | 2009-12-16 | Vrije Universiteit Brussel | Immunoglobulines dépourvus de chaînes légères |
| DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| WO2001019866A1 (fr) | 1999-09-10 | 2001-03-22 | The University Of Sydney | Dipeptidyl peptidases |
| EP1268550A2 (fr) | 2000-03-17 | 2003-01-02 | Boehringer Ingelheim Pharma KG | Anticorps humains specifiques de fap-alpha |
| GB0027552D0 (en) | 2000-11-10 | 2000-12-27 | Boehringer Ingelheim Pharma | Anti-tumor compounds |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| AU2006246719A1 (en) | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| AU2006264305B2 (en) | 2005-07-05 | 2012-07-05 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein alpha |
| EP1760076A1 (fr) | 2005-09-02 | 2007-03-07 | Ferring B.V. | Inhibiteur de FAP |
| EP1806365A1 (fr) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués |
| EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
| EP2328920A2 (fr) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Polypeptides co-stimulateurs ciblés et leurs procédés d'utilisation dans le traitement du cancer |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| BRPI0919818A2 (pt) | 2008-09-25 | 2019-09-24 | Molecular Insight Pharm Inc | inibidores de seprase seletivos |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| US20120053222A1 (en) | 2009-01-23 | 2012-03-01 | Mark Gorrell | Novel Metabolic Disease Therapy |
| US8345509B2 (en) | 2009-04-16 | 2013-01-01 | Chevron U.S.A., Inc. | System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole |
| CA2773515C (fr) | 2009-09-29 | 2015-04-28 | Roche Glycart Ag | Anticorps agonistes bispecifiques du recepteur de mort |
| JP2013506664A (ja) | 2009-10-02 | 2013-02-28 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド | 抗線維芽細胞活性化タンパク質抗体並びにその方法及び使用 |
| EP2504028A4 (fr) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | Inhibition simultanée de pd-l1/pd-l2 |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| SG187746A1 (en) | 2010-08-13 | 2013-03-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| US20120213781A1 (en) | 2011-02-11 | 2012-08-23 | Zyngenia, Inc. | Monovalent and Multivalent Multispecific Complexes and Uses Thereof |
| JP6207509B2 (ja) | 2011-08-30 | 2017-10-04 | トラスティーズ オブ タフツ カレッジ | 固形腫瘍を治療するためのfap活性化プロテアソーム阻害剤 |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-pd-l1 항체 및 그의 용도 |
| EP2804859B1 (fr) | 2012-01-17 | 2019-06-12 | Universiteit Antwerpen | Nouveaux inhibiteurs de fap |
| AR092745A1 (es) | 2012-10-01 | 2015-04-29 | Univ Pennsylvania | Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer |
| US9593148B2 (en) | 2012-11-02 | 2017-03-14 | Georg-August-Universitat Gottingen Stiftung Offentlichen Rechts | DPP8 and DPP9 peptide inhibitors |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| HRP20181251T1 (hr) | 2013-09-06 | 2018-10-05 | Aurigene Discovery Technologies Limited | Derivati 1,3,4-oksadiazola i 1,3,4-tiadiazola kao imunomodulatori |
| CU24362B1 (es) | 2013-09-06 | 2018-10-04 | Aurigene Discovery Tech Ltd | Derivados de 1,2,4-oxadiazol como inmunomoduladores |
| CN116059219A (zh) * | 2015-07-16 | 2023-05-05 | 比奥克斯塞尔医疗股份有限公司 | 一种使用免疫调节治疗癌症的新颖方法 |
| US11613785B2 (en) | 2017-01-09 | 2023-03-28 | Onkosxcel Therapeutics, Llc | Predictive and diagnostic methods for prostate cancer |
-
2018
- 2018-01-09 US US16/476,420 patent/US11613785B2/en active Active
- 2018-01-09 EP EP18736583.8A patent/EP3565560B1/fr active Active
- 2018-01-09 WO PCT/US2018/012876 patent/WO2018129497A1/fr not_active Ceased
- 2018-01-09 MA MA047215A patent/MA47215A/fr unknown
- 2018-01-09 ES ES18736583T patent/ES2988845T3/es active Active
-
2023
- 2023-01-20 US US18/157,717 patent/US20230227918A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3565560A1 (fr) | 2019-11-13 |
| EP3565560B1 (fr) | 2024-05-29 |
| US20210355541A1 (en) | 2021-11-18 |
| WO2018129497A1 (fr) | 2018-07-12 |
| US20230227918A1 (en) | 2023-07-20 |
| ES2988845T3 (es) | 2024-11-21 |
| US11613785B2 (en) | 2023-03-28 |
| EP3565560A4 (fr) | 2021-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271888A (en) | Therapeutic and diagnostic methods for cancer | |
| EP3692164A4 (fr) | Marqueurs de méthylation pour le diagnostic du cancer | |
| IL274246A (en) | Methods for diagnosing and treating cancer | |
| IL325217A (en) | Cancer treatment and diagnosis methods | |
| IL268396A (en) | Diagnostic and therapeutic methods for cancer | |
| IL265759A (en) | Therapeutic and diagnostic methods for cancer | |
| IL261422A (en) | Therapeutic and diagnostic methods for cancer | |
| EP3565560A4 (fr) | Procédés prédictifs et diagnostiques pour le cancer de la prostate | |
| IL264674B1 (en) | Antibodies to siglec7 for cancer treatment | |
| IL255312A0 (en) | Therapeutic and diagnostic methods for cancer | |
| IL256025A (en) | Methods of diagnosing and treating cancer | |
| IL262208A (en) | Diagnostic and therapeutic methods for cancer | |
| IL270717A (en) | Biomarkers for diagnosis of lung cancer | |
| EP3403093A4 (fr) | Biomarqueurs de type auto-anticorps plasmatiques pour le diagnostic du cancer du poumon | |
| EP3490677A4 (fr) | Marqueurs lipidiques, protéiques et métaboliques pour le diagnostic et le traitement du cancer de la prostate | |
| ZA201801024B (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer | |
| EP3383407A4 (fr) | Conjugués de cytarabine pour le traitement du cancer | |
| ZA202000851B (en) | Antibodies useful in cancer diagnosis | |
| EP3359696A4 (fr) | Test diagnostique pour surveillance urinaire du cancer de la vessie | |
| EP3469101A4 (fr) | Procédés et compositions pour le diagnostic et le traitement du cancer de la prostate | |
| HUE054864T2 (hu) | In vitro módszer tüdõrák diagnosztizálására | |
| EP3341079A4 (fr) | Procédés et compositions pour le diagnostic et le traitement du cancer | |
| MA40636A (fr) | Procédés pour détecter le cancer de la prostate | |
| EP3419526A4 (fr) | Procédés et dispositifs pour le diagnostic des trompes de fallope | |
| EP3839513C0 (fr) | Utilisation de complexes de facteur de transcription-adn pour la détection du cancer |